Company Analysis
Sign in

Protara Therapeutics, Inc. (TARA)

Nasdaq: TARA · Biological Products, (No Diagnostic Substances) · New York, NY · filing with the SEC since 2006
Full chart Alerts Compare
Grade5.0
◀ Past 4.0● Present 5.9▶ Future 4.9
6 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart
The companyfiscal 2014, as filed
Revenue$2.9M
Net incomen/a
Earnings per sharen/a
Operating cash flown/a
Cashn/a
Debtn/a
Shareholders’ equityn/a
Shares, dilutedn/a
Return on equity-29.2%
The recordfrom its filings
Filings in 202669
Newest filingNov 6 · 10-Q
Annual reportMar 10, 2026
Quarterly reportNov 6, 2026
Next report due10-K by Mar 31
Insider sales, 12 months$1.0M
Insider buys, 12 months$0.00
Patents granted16
Filer categoryNon-accelerated filer<br>Smaller reporting company
Trailing twelve months to Sep 2026Net income -$78.4MCash from operations -$72.1Mthe four newest filed quarters added
Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.
Revenue and net income by fiscal yearRevenueNet income
16171819202122232425
As filed, in USD. Nothing here is a forecast.

News

Nov 6, 2026 · SEC EDGAR · Form 10-Q
Quarterly report
Open the filing on sec.gov
Nov 6, 2026 · SEC EDGAR · Form 8-K
Results released
Open the filing on sec.gov
Aug 11, 2026 · SEC EDGAR · Form 10-Q
Quarterly report
Open the filing on sec.gov
Aug 11, 2026 · SEC EDGAR · Form 8-K
Current report
Open the filing on sec.gov
Jul 1, 2026 · SEC EDGAR · Form 4
Insider trade report
Open the filing on sec.gov
Jun 29, 2026 · SEC EDGAR · Form 8-K
Current report
Open the filing on sec.gov
An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.
SI Assistanton TARA · research, not advice